Order Article Reprints

Nikoloudis A, Strassl I, Binder M, Stiefel O, Wipplinger D, Milanov R, Aichinger C, Kaynak E, Machherndl-Spandl S, Buxhofer-Ausch V, et al. Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation. Transplantology. 2023; 4(1):22-37. https://doi.org/10.3390/transplantology4010005

Nikoloudis, Alexander, Irene Strassl, Michaela Binder, Olga Stiefel, Dagmar Wipplinger, Robert Milanov, Christoph Aichinger, Emine Kaynak, Sigrid Machherndl-Spandl, Veronika Buxhofer-Ausch, and et al. 2023. "Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation" Transplantology 4, no. 1: 22-37. https://doi.org/10.3390/transplantology4010005

Nikoloudis, A., Strassl, I., Binder, M., Stiefel, O., Wipplinger, D., Milanov, R., Aichinger, C., Kaynak, E., Machherndl-Spandl, S., Buxhofer-Ausch, V., Böhm, A., Petzer, A., Weltermann, A., Wolf, D., Nachbaur, D., & Clausen, J. (2023). Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation. Transplantology, 4(1), 22-37. https://doi.org/10.3390/transplantology4010005